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’INTRODUCTION
Lantibiotics are ribosomally synthesized antimicrobial pep-
tides that undergo extensive post-translational modiﬁcations to
attaintheiractiveantimicrobialforms.
1Theyarecharacterizedby
thepresenceofthioethercross-linkedaminoacidscalledlanthio-
nine (Lan) and methyllanthionine (MeLan), which are formed
by intramolecular addition of cysteine thiols to dehydroalanine
(Dha) and dehydrobutyrine (Dhb) residues, respectively. The
dehydroalanines are generated by dehydration of Ser residues,
whereas the dehydrobutyrines are formed by dehydration of
threonines.
1 Cinnamycin is a 19 amino acid lantibiotic with
antimicrobial activity against gram-positive rods such as bacilli,
Clostridium botilinum, and Mycobacterium.
2 The compound also
causes transbilayer phospholipid movement in the cell mem-
brane of mammalian cells to access phosphotidylethanolamine
(PE)residingpredominantlyintheinnerleaﬂetofthemembrane.
3
The interaction of cinnamycin with PE has provided researchers
with tools to monitor PE
4 and also renders the compound phar-
macologically valuable. For example, duramycin, a close structural
analogue of cinnamycin, promotes chloride secretion in lung
epithelial cells by binding to PE; this activity in turn promotes
mucus clearance from the lungs. As a result, the compound is in
phase II clinical trials for the treatment of cystic ﬁbrosis,
5 7 a
common genetic disorder characterized by abnormal chloride
ion transport.
6 Cinnamycin has also been suggested as an
alternative treatment for atherosclerosis through its ability to
inhibit phospolipase A2 by binding to its substrate PE.
8,9
Cinnamycin has a compact globular structure with one Lan
and two MeLan residues in addition to an unusual lysinoalanine
(Lal) formed from lysine 19 and serine 6 (Figure 1).
10,11 Unlike
most lantibiotics, the rings are generated in a bidirectional
manner such that the MeLan bridges are formed by cysteines
that are located N-terminal to the dehydrobutyrine residues
with which they react, and the Lan bridge is formed from a
cysteine located C-terminal to the dehydroalanine with which it
reacts.Similarly,theLalisgeneratedfromaLyslocatedC-terminal
to the serine with which it forms a cross-link. Unlike the Lan and
MeLanstructures,whichhave D-stereochemistryattheR-carbon
originating from Dha/Dhb, the Lal has the L-conﬁguration at the
R-carbon originating from Ser,
12,13 raising the question whether
it is formed with the intermediacy of a Dha or not.
In addition to the macrocyclic structures, cinnamycin also
contains an erythro-3-hydroxy-L-aspartic acid resulting from
the hydroxylation of L-aspartate at position 15 (Figure 1).
10,12
The binding of cinnamycin to its target PE is mediated by
interaction of this post-translational modiﬁcation with the
ammonium group of PE.
8,14 The duramycins (duramycin,
duramycin B and C) are natural analogues of cinnamycin with
the same number of amino acids and very high sequence
similarity including identical positions of the four cross-links
and the hydroxylated Asp.
13
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ABSTRACT: Lantibiotics are ribosomally synthesized and
post-translationally modiﬁed antimicrobial peptides that are
characterized by the thioether cross-linked amino acids lanthio-
nine (Lan) and methyllanthionine (MeLan). Cinnamycin is a
19aminoacidlantibioticthatcontainsoneLanandtwoMeLan.
Cinnamycinalsocontainsanunusuallysinoalanine (Lal)bridge
formedfromtheε-aminogroupoflysine19andaserineresidueatposition6,andanerythro-3-hydroxy-L-asparticacidresultingfrom
the hydroxylation of L-aspartate at position 15. These modiﬁcations are critical in mediating the interactions of cinnamycin with its
target, phosphatidylethanolamine. Recently, the cinnamycin biosynthetic gene cluster (cin) from Streptomyces cinnamoneus
cinnamoneus DSM 40005 was reported. Herein, we investigated the biosynthetic machinery using both in vitro studies and
heterologous expression in Escherichia coli. CinX is an R-ketoglutarate/iron(II)-dependent hydroxylase that carries out the
hydroxylation of aspartate 15 of the precursor peptide CinA. In addition, CinM catalyzes dehydration of four Ser and Thr residues
and subsequent cyclization of Cys residues to form the three (Me)Lan bridges. The order of the post-translational modiﬁcations
catalyzed by CinM and CinX is interchangeable in vitro. CinX did not require the leader sequence at the N-terminus of CinA for
activity, but the leader peptide was necessary for CinM function. Although CinM dehydrated serine 6, it did not catalyze the
formationofLal.Asmallproteinencodedbycinorf7iscriticalfortheformationofthecross-linkbetweenLys19anddehydroalanine
6 as shown by coexpression studies of CinA, CinM, CinX, and Cinorf7 in E. coli.13754 dx.doi.org/10.1021/ja205783f |J. Am. Chem. Soc. 2011, 133, 13753–13760
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Recently, the cinnamycin biosynthetic gene cluster (cin) from
Streptomyces cinnamoneus cinnamoneus DSM 40005 was reported,
15
providing opportunities to investigate the biochemistry of its
biosynthetic pathway. Lantibiotics are produced from precursor
peptides termed LanA that have an N-terminal sequence called
the leader peptide that is recognized by various enzymes to
process the C-terminal core peptide.
16 (Me)Lan intramolecular
bridges are formed by enzymatic dehydration of speciﬁc Ser and
Thr residues to form Dha and Dhb residues followed by
subsequent stereoselective intramolecular Michael-type addition
of cysteine thiols to these dehydroamino acids. Lanthionine
synthetases are divided into four classes based on sequence
homology.
17 19 In class II lantibiotics to which cinnamycin
belongs, both dehydration and cyclization are catalyzed by a
bifunctional enzyme called LanM.
20 After the core peptide is
processed,theleader peptideisremoved proteolyticallytoaﬀord
the mature, biologically active compound.
21
The cinnamycingeneclustercontains 21 open readingframes
(17083bp),whichincludethegenesforcinnamycinproduction,
regulation, and self-resistance (Figure S1).
15 The cinnamycin
precursorpeptide,CinA,consistsofaC-terminalcoreregionthat
is 19 residues long and that will be transformed into cinnamycin
through post-translational modiﬁcations. Appended to the N-
terminus of the core peptide is an unusually long 59 amino acid
leader sequence that is not modiﬁed. Instead of a GG or GA
protease cleavage motif seen in most class II lantibiotics, an AXA
motifispresentbetweentheleadersequenceandthecoreregion
of CinA (Figure 1). This sequence is recognized by type I signal
peptidases of the general secretory (sec) pathway,
22 which
explains the absence of a cinnamycin-speciﬁc protease in the
gene cluster.
15 The CinM sequence shows high homology with
other class II LanM enzymes.
15 However, the enzymes respon-
sible for Asp hydroxylation and Lal bridge formation have not
been explored.
Understanding the biosynthetic pathway of cinnamycin may
be used to generate analogues with potentially improved proper-
ties for treatment of cystic ﬁbrosis or clostridium infections.
Herein, we investigated the biosynthetic machinery of cinnamy-
cin in vitro and characterized the enzymes involved in the
formation of the thioether cross-links and the β-hydroxylation
of aspartate 15. In addition, we developed a coexpression system
in E. coli that resulted in fully modiﬁed CinA and identiﬁed
cinorf7, an open reading frame of unknown function, as a critical
determinant for lysinoalanine formation.
’RESULTS
In Vitro Reconstitution of the Enzymatic Activity of the
Lanthionine Synthetase, CinM. The gene for the precursor
peptide CinA was cloned into a pET15b vector, and the gene
encoding CinM was cloned into a pET16b vector to generate
N-terminal histidine-tagged fusion proteins upon heterologous
expression. Site-directed mutagenesis was used to mutate the
alanine residue at the last position of the leader peptide of CinA
(position 1)tolysine.TheresultingHis6-CinA(A 1K)mutant
enables removal of the leader peptide using the commercial
endoproteinase LysC for bioactivity assays. This substrate ana-
logue was used as a precursor peptide throughout this study.
Both His6-CinA(A 1K) and His10-CinM were heterologously
expressed in E. coli BL21 (DE3) cells and purified by immobi-
lized metal ionaffinitychromatography(IMAC).Approximately
6 10 mg of His10-CinM was obtained per liter of cell culture.
TheHis6-CinA(A 1K) peptidewas further purified after IMAC
by reverse-phase high-performance liquid chromatography (RP-
HPLC) resulting in 40 mg of purified peptide per liter of cell
culture that was detected as the Na
+ adduct after LysC protease
cleavage(Figure2A).TheenzymeCinMmigratedasaproteinof
approximately 120 kDa by sodium dodecyl sulfate polyacryla-
midegel electrophoresis (SDS-PAGE) and gelfiltration analysis,
close to the predicted monomeric molecular weight of His10-
CinM (118.8 kDa) (Figure S2).
Toevaluatedehydrationactivity,His6-CinA(A 1K)(20μM)
was incubated with His10-CinM (5 μM) at 25 C for 6 h in the
presence of adenosine triphosphate (ATP), MgCl2, and immo-
bilized tris(2-carboxyethyl)phosphine (TCEP). Use of immobi-
lized reducingagentwasrequiredtoprevent unwantedadditions
of reducing agents (TCEP/dithiothreitol) to the dehydrated
precursorpeptide.Analysisofthecorepeptidebymatrix-assisted
laser desorption/ionization time-of-ﬂight mass spectrometry
(MALDI-ToF MS) after LysC endoproteinase treatment re-
vealed a mass corresponding to loss of four water molecules
(Figure2B).Thisﬁnding demonstrates that CinM is responsible
forthedehydrationofthetwothreonine(Thr11andThr18)and
two serine residues (Ser4 and Ser6) in the core region of CinA.
Addition of cysteine thiols to the dehydroamino acids does not
causeachangeinmass,whichpreventsobservationofcyclization
by MALDI-ToF MS. To investigate the cyclization activity of
CinM,iodoacetamide(IAA),athiolalkylatingagentthatinduces
Figure 1. The structure of cinnamycin. Lan and MeLan are shown in
redandblue,respectively,Lalisdepictedinpurple,andthehydroxylated
Asp is shown in green. The sequence of the CinA core and leader
peptides isdepicted aswellastheresidues thatformthecross-links. The
sec-cleavage sequence at the end of the leader peptide is shown in bold
underlined font.13755 dx.doi.org/10.1021/ja205783f |J. Am. Chem. Soc. 2011, 133, 13753–13760
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a mass increase upon reaction with cysteine thiols, was used.
His6-CinA(A 1K) and His6-CinA(A 1K) modiﬁed by His10-
CinM were treated with IAA and LysC protease and then subjected
to MALDI-ToF MS analysis. As expected, His6-CinA(A 1K)
that had not been treated with His10-CinM showed a mass
increase corresponding to alkylation of the three cysteines in the
core peptide (Figure 2D). In contrast, only minor alkylation
products were observed in the His10-CinM treated sample
(Figure 2C). The data strongly support conversion of the
majority of the free thiols to thioether rings by His10-CinM,
although one Cys
23 appears to be less eﬃciently cyclized result-
ing in some peptide with one IAA adduct (Figure 2C). Taken
together, these results demonstrate that CinM functions as a
bifunctional LanM enzyme that catalyzes both dehydration and
cyclization reactions to form the thioether cross-links. CinM did
not, however, form the lysinoalanine (vide infra).
Quantitative Analysis of Zinc Bound to CinM. Metal
analysis of the cyclase enzymes involved in subtilin (SpaC) and
nisin (NisC) biosynthesis demonstrated that these proteins
contained 1 equiv of zinc.
24,25 These results were confirmed
with the crystal structure of NisC.
26 The zinc has been proposed
to activate the Cys thiols of the peptide substrate for intra-
molecular addition to the dehydro amino acids in the substrate.
Todate,nostructuralinformationisavailableforLanMenzymes.
However, because LanM enzymes share sequence homology at
the C-terminus with LanC cyclases (20 30% identity), includ-
ing two Cys and one His that coordinate to the Zn
2+ in LanC
proteins, it was hypothesized that the LanM cyclase domains
might act through a similar mechanism of zinc-mediated activa-
tion of the Cys thiols in LanA substrates.
27
To test if CinM contained zinc, a spectrophotometric assay
wasperformedusingthemetallochromicindicator4-(2-pyridylazo)-
resorcinol (PAR).
28 Treatment of His10-CinM with 5,50-
dithiobis(2-nitrobenzoic acid) (DTNB) under denaturing con-
ditions(6Mguanidinehydrochloride)convertedCysresiduesin
CinM to disulﬁdes including any metal ligands. As a result,
DTNB facilitates release of the active site zinc,
24 which sub-
sequently formed the orange Zn (PAR)2 complex that was
monitored by absorbance at 500 nm. Corrections for DTNB
absorbance levels were applied, and a linear standard plot
determined from zinc standards was used to calculate the
CinM:zinc ratio. On the basis of this experiment, His10-CinM
was found to bind 1.05 equiv of zinc.
In Vitro Reconstitution of CinX. The cinX gene was cloned
into pET28b, and the encoded protein was heterologously
expressed in E. coli with an N-terminal His6-tag and was purified
by IMAC. His6-CinX migrated as a monomer of approximately
38 kDa in gel filtration and SDS-PAGE analysis (Figure S2).
Sequence analysis suggested that CinX may be a member of
the nonheme Fe(II)-dependent family of enzymes that utilizes
R-ketoglutarate (R-KG) as cofactor.
His6-CinA(A 1K) was modiﬁed with His10-CinM followed
by His6-CinX treatment in the presence of Fe(II) and R-KG for
2h.AftersubsequentdigestionwithLysC,fourdehydrationsand
a hydroxylation were observed in the core region of CinA by
MALDI-MS (Figure 3).In theabsenceofeitherFe(II)or R-KG,
no mass change corresponding to hydroxylation was observed,
which supports the hypothesis from its sequence that CinX is an
R-ketoglutarate/Fe(II)-dependent hydroxylase.
The order in which CinM and CinX may carry out their post-
translational modiﬁcations was also investigated. In vitro these
twoenzymesdidnothave acompulsoryorder ofactionas His10-
CinMwasabletodehydrateandcyclizeHis6-CinAthathadbeen
hydroxylated by His6-CinX (Figure S3), and His6-CinX was able
to hydroxylate His6-CinAthat had been dehydrated and cyclized
Figure 2. MALDI-ToF MS analysis of IAA modiﬁcation assay of CinA
modiﬁed in vitro by CinM. (A) MALDI ToF MS of His6-CinA(A 1K)
treated with LysC, (B) MALDI ToF MS of His6-CinA(A 1K) after
incubation with His10-CinM followed by LysC treatment, (C) MALDI
mass spectrum of His6-CinA(A 1K) after incubation with His10-CinM
followedbyIAAandLysCtreatment,and(D)MALDImassspectrumof
His6-CinA(A 1K) after IAA and LysC treatment. CP = CinA core
peptide.13756 dx.doi.org/10.1021/ja205783f |J. Am. Chem. Soc. 2011, 133, 13753–13760
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(Figure3).Tovalidatethesiteofhydroxylation,aspartate15was
mutated to alanine, and the mutant CinA peptide was incubated
with His6-CinX. MALDI ToF MS analysis showed no change in
the mass of the mutant peptide (data not shown). In lantibiotics,
theleader peptideisrequired foractivityof mostof thebiosynthetic
enzymes.
21 To evaluate if this requirement was also the case for
His10-CinM andHis6-CinX, the core peptide of CinA (CinA1 19)
was synthesized by solid-phase peptide synthesis. As expected,
His10-CinM showed no activity in the absence of the leader
peptide (Figure S4A). In contrast, His6-CinX was capable of
hydroxylating CinA(1 19) (Figure S4B). LC MS/MS analysis
of the product further veriﬁed that the hydroxylation occurs on
Asp15 (Figure S5).
Lysinoalanine Formation and Bioactivity Assays. Genetic
studies in the producing organism have shown that cinA, cinM,
cinX, and cinorf7 are required for formation of cinnamycin.
29
Having assigned the function of the first two enzymes, we
investigated whether Cinorf7 was responsible for Lal formation.
Cinorf7 was expressed in E. coli, purified as an N-terminal hexa
histidine fusion protein, and added to various assays containing
His6-CinA and His10-CinM and/or His6-CinX, with various
orders of addition and supplementation with cofactors. Unfortu-
nately, Lal was not formed under any conditions as determined
using a variety of assays described below. Nonenzymatic forma-
tionofLal, whichresults inboth Land Dconfigurations,has been
observed infood products under alkaline conditions bychemical
dehydration of Ser or elimination from Cys/cystine and sub-
sequentnonselectiveconjugateadditionoflysinetotheresulting
Dha.
30 On the basis of these observations, we investigated the
nonenzymatic in vitro formation of the Lal ring under mild
alkaline conditions (pH 9.5) after the precursor peptide His6-
CinA(A 1K) had been processed with His10-CinM and His6-
CinX. The leader peptide was removed with LysC endoprotei-
nase, and the resulting product was analyzed for Lal formation.
The product was first hydrolyzed in strongly acidic conditions,
andtheresultingaminoacidswerederivatizedtothecorrespond-
ing methyl estersand pentafluoropropionyl amides.
31,32 Authen-
tic cinnamycin was subjected to the same treatment to provide a
standard. Subsequent analysis by gas chromatography tandem
mass spectrometry (GC MS/MS) demonstrated that deriva-
tized Lal from authentic cinnamycin eluted as two peaks,
probably due to epimerization during the acidic hydrolysis.
30
The same retention times for these two peaks were observed for
Lalderivedfrombothauthenticcinnamycinandtheinvitroassay
sample (Figure S6A and B). The fragmentation pattern of the
peaks in the GC MS was also identical to and consistent with
those in the literature for lysinoalanine derivatives (Figure S6C
and D).
33 Thus, these experiments verify formation of the lysinoa-
lanine ring at increased pH, but because the Lal residue originating
from authentic cinnamycin was epimerized, we were unable to
establish whether nonenzymatic Lal formation was stereoselective.
To investigate ifthe nonenzymatic Lal cyclization product has
the correct stereochemistry, an antimicrobial assay was em-
ployed, under the assumption that cyclization with the incorrect
stereochemistry would give an inactive product. A well diﬀusion
assay against the indicator strain B. subtilis LH45 demonstrated
clear antimicrobial activity of cinnamycin synthesized in vitro. A
sample that was not treated under alkaline conditions did not
produce a zone of growth inhibition, which demonstrates the
requirement of Lal for antimicrobial activity of cinnamycin.
Unfortunately, this in vitro process to produce cinnamycin did
notallowcomparisonofitsbioactivitywithauthenticcinnamycin
because the sample contained unknown amounts of material
derived from the biosynthetic enzymes, the leader peptide, and
LysC. Therefore, the concentration of cinnamycin within the
sample was not known. Attempts to purify the cyclized core
peptide by reverse phase high-performance liquid chromatogra-
phy (RP-HPLC) produced very low quantities of cinnamycin,
preventing comparison with authentic cinnamycin.
CoexpressionofCinA,CinM,andCinXinE.coli.Quantifica-
tion of Lal formation after alkaline treatment by GC MS has
been challenging because of the large background resulting from
the leader peptide and the biosynthetic enzymes. In an effort to
improveboththeamountsofmaterialandtheirpurity,weturned
to coexpression of the CinA peptide and the CinM and CinX
modificationenzymesinE.coli.Recentstudiesinseverallaboratories
have demonstrated the feasibility of conducting the post-transla-
tional modifications that generate lantibiotics in this heterologous
host.
34 37 In our laboratory, pRSFDuet-1 and pACYCDuet-1
plasmids were used for these studies, which offer convenient
purification of the post-translationally modified peptide using
IMAC because of a His6-tag at the N-terminus of the leader
peptide of the substrate peptide.
35 A similar approach was
employed here in an attempt to obtain higher quantities of
peptide processed by CinM and CinX.
The gene encoding CinA(A 1K) with an N-terminal ﬂag
tag
38 was inserted into multiple cloning site I (MCSI) of the
pRSFDuet-1 vector to generate His6-Flag-CinA(A 1K). The
gene encoding CinM was inserted into MCSII of the same
plasmid resulting in a protein without a His-tag, thus preventing
copuriﬁcation of the CinM enzyme, which complicated the in
vitro experiments. Similarly, cinX was cloned into MCSII of the
pACYCDuet-1 vector, which also produces CinX without a
His-tag. Coexpression of CinM and CinX together with His6-
Flag-CinA(A 1K) yielded 2 mg of His6-Flag-CinA(A 1K)
peptide per liter of cell culture after IMAC puriﬁcation, and
subsequent RP-HPLC. MALDI-ToF MS analysis of the LysC-
treated peptide showed a mass diﬀerence with respect to
unmodiﬁed core peptide corresponding to four dehydrations
and one hydroxylation (Figure S7A). In vivo thioether cycliza-
tion activity was investigated by IAA treatment and analysis by
Figure 3. MALDI-ToF MS analysis of hydroxylation by CinX. His6-
CinA(A 1K) modiﬁed by His10-CinM and subsequently digested with
LysC is shown in black. His6-CinA(A 1K) modiﬁed by His10-CinM
andthenHis6-CinXandsubsequentdigestionwithLysCisshowninred.
Changing the order of modiﬁcation by His10-CinM and His6-CinX
resulted in the same product as shown in Figure S3. CP = CinA core
peptide.13757 dx.doi.org/10.1021/ja205783f |J. Am. Chem. Soc. 2011, 133, 13753–13760
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MALDI-ToF MS as previously described. Similar to the in vitro
results, CinM formed predominantly three thioether rings in the
CinA core region (Figure S7B).
The peptide obtained from coexpression did not have anti-
microbial activity toward the indicator strain B. subtilis LH45
similar to the observations for the product of CinM and CinX
treatmentinvitro.However,whenLalcyclizationwasinducedby
mildalkalinetreatment,thepeptideshowed strongantimicrobial
activity comparable to authentic cinnamycin (Figure 4).
With larger quantities of material in hand, the peptide
produced in E. coli was used to investigate nonenzymatic Lal
formation in more detail. o-Phthalaldehyde (OPA) is a reagent
that reacts selectively with primary amines in the presence of a
thiol such as β-mercaptoethanol but does not react with second-
ary amines.
39 Thus, OPA was used to monitor conversion of the
primary ε-amine of Lys to the secondary amine in Lal. CinA that
had been modiﬁed by CinM and CinX in E. coli and then
incubated with LysC was treated with OPA, causing a mass
increase corresponding to two OPA additions in the core
peptide. These two OPA adducts originate from the N-terminal
amino group and the ε-amino group of Lys. Furthermore, one
β-mercaptoethanol addition was observed as a consequence of
Michael-type addition to dehydroalanine 6 (Figure 5A). Collec-
tively, these data clearly show the absence of a lysinoalanine. In
contrast, the OPA assay of the same sample after alkaline
treatment resulted in only one OPA addition and no β-mercap-
toethanol adducts, which was also observed when authentic
cinnamycin was used as a positive control (Figure 5B,C). The
absence of the peak corresponding to the formation of two OPA
and one β-mercaptoethanol adducts in this sample suggests that
the cyclization occurred with near quantitative eﬃciency.
Coexpression of CinA, CinM, CinX, and Cinorf7 in E. coli.
Theinvitrostudiesdidnotprovide anyinsightsintothepossible
role of Cinorf7 in cinnamycin biosynthesis. In an alternative
approach, the coexpression system in E. coli was used to
investigate whether Cinorf7 is involved in formation of the Lal
in vivo. For this purpose, the cinorf7 gene was cloned into MCSI
of pACYCDuet-1 that already contained the gene encoding
CinX in MCSII. The resulting plasmid was used with the
pRSFDuet-1 vector containing the genes for CinA(A 1K) and
CinM for coexpression in E. coli. The modified CinA(A 1K)
peptide was purified by IMAC, treated with LysC, and analyzed
with the OPA assay. The resulting mass spectrum showed that
the Lal structure was formed without the need of raising the pH
(Figure S8A). Also, an antimicrobial assay toward the indicator
strain B. subtilis LH45 verified that the activity of cinnamycin
synthesized heterologously in E. coli is similar to the antimicro-
bialactivityofauthenticcinnamycin(FigureS8B).Becauseinthe
absence of Cinorf7 both the OPA assay and the antimicrobial
assay were negative for the peptide produced in E. coli, these
resultsrevealthatCinorf7isrequiredfortheformationoftheLal.
’DISCUSSION
The in vitro biosynthesis of cinnamycin was achieved in this
work by reconstitution of the activities of two enzymes in the
Figure 4. Bioassay with the indicator strain B. subtilis LH45. Sector 1,
authentic cinnamycin; sector 2, His6-CinA(A 1K) modiﬁed by CinM
and CinX in E. coli and treated with LysC followed by incubation at pH
9.5; sector 3, His6-CinA(A 1K) modiﬁed by CinM and CinX in E. coli
treated with LysC (no alkaline treatment); sector 4 was not used.
Figure 5. Use of o-phthalaldehyde (OPA) to monitor lysinoalanine
formation. (A) CinA(A 1K) modiﬁed by CinM and CinX and treated
with LysC was incubated with OPA and β-mercaptoethanol. (B)
CinA(A 1K) modiﬁed by CinM and CinX followed by alkaline
treatment and removal of the leader peptide with LysC was incubated
with OPA and β-mercaptoethanol. (C) Authentic cinnamycin was
incubatedwithOPAandβ-mercaptoethanol.SM=massofcorepeptide
after four dehydrations and one hydroxylation. Asterisk indicates 4-fold
dehydrated core peptide that did not react with OPA.13758 dx.doi.org/10.1021/ja205783f |J. Am. Chem. Soc. 2011, 133, 13753–13760
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biosynthetic pathway, CinM and CinX. His10-CinM dehydrated
two threonineandtwoserineresidues inthecore region ofHis6-
CinA and catalyzed the subsequent cyclization by cysteine thiols
to form three thioether rings. The observation that CinM
dehydrated Ser6 conﬁrms that the Lal is formed with the
intermediacy of a dehydroalanine despite the L-stereochemistry
at the R-carbon of the former Ser residue. Although His10-CinM
dehydratedSer6,itdid notcatalyzetheformationof the Lal ring.
Considering that LanC/LanM enzymes typically stereoselec-
tively protonate the enolate formed during the Michael-type
addition to provide D-stereochemistry at the R-carbon, it is not
surprisingthatLalformation,whichresultsinthe L-conﬁguration
at the newly formed stereogenic center,
12,13 is not catalyzed by
CinM. In addition, CinM is much better suited to activate a thiol
nucleophile with the Zn
2+ in its active site than to activate a
primary amine.
CinX is shown to be an Fe(II)/R-ketoglutarate-dependent
hydroxylase that catalyzes the β-hydroxylation of Asp15 in the
CinA precursor peptide. Interestingly, His6-CinX accepted the
core region of CinA as a substrate without the need of the leader
sequence. Similar observations were made for the oxidative
decarboxylase EpiD,
40 suggesting that tailoring enzymes that
introduce post-translational modiﬁcations beyond dehydration
and cyclization may not require the leader peptide. However, as
observed for other lanthionine synthetases,
41 43 His10-CinM
requiredtheleaderpeptideforeﬃcientprocessing.Changingthe
order of incubation of the precursor peptide with His10-CinM or
His6-CinX resulted in the same product.
In vitro biosynthesis of cinnamycin was accomplished by
inducing nonenzymatic formation of the Lal by raising the pH
after treatment of CinA with His10-CinM and His6-CinX in vitro
or after heterologous coexpression of CinM and CinX with the
precursor peptide in E. coli. The high bioactivity of the resulting
peptide suggests that the nonenzymatic cyclization occurs with
high stereoselectivity, assuming that cinnamycin with a Lal
residue with incorrect stereochemistry has no or low antimicro-
bial activity. At present, we cannot test this assumption, but high
stereoselectivity for nonenzymatic formation of Lan and MeLan
has been demonstrated previously.
44 49 No such investigations
have been conducted for Lal formation, but a previous study on
the structure elucidation of cinnamycin concluded that the
alternative conﬁguration of Lal results in high strain energy.
12
The Lan and MeLan residues generated by CinM may preorga-
nize the conformation of the peptide to favor stereoselective
formation of Lal, similar to a recent proposal for a lanthionine
synthetase that generates a large number of thioether cross-links
of high structural diversity.
32
Genetic studies have identiﬁed the cinorf7 gene to be essential
inthebiosynthesispathwayofcinnamycin.
29Thisgene,composed
of just 360 nucleotides, is located immediately upstream of cinA
and the two genes are cotranscribed.
15 We show here that
Cinorf7 is required for lysinoalanine formation. Unfortunately,
invitroreconstitutionofitsactivityhasbeenunsuccessfultodate.
Sequence analysis of Cinorf7 shows that it does not have
signiﬁcant homology to other functionally characterized pro-
teins. Two other genes encoding proteins with high sequence
similarity to Cinorf7 were identiﬁed in the protein databases
(Figure S9A). One of these, found in the genome of Lyngbya
majuscule, has two nearby likely precursor peptides, whereas the
second, found in the genome of Frankia Sp., has one gene
encodingapossibleprecursorpeptidenearby(FigureS9B).Both
cinorf7 orthologues also are near LanM-like genes. Although the
sequencesofthepredictedleaderpeptidesoftheseputativeprecursor
peptides vary, their core regions showed very high sequence
identity to the cinnamycin group of lantibiotics (Figure S9B),
suggesting these gene clusters have the genetic capacity to
generate cinnamycin-like peptides.
Insummary,wedemonstrateherethatCinMisresponsiblefor
dehydration of two Ser and two Thr residues and also generates
the three thioether cross-links in cinnamycin. Furthermore, we
show that CinX hydroxylates a single Asp in a 78-residue
substrate and that it also accepts just the core peptide as
substrate. Finally, our data indicate that Cinorf7 is critical for
the formation of the unique cross-linked lysinoalanine. These
studies set the stage for the generation of cinnamycin analogues
and investigations of the mechanism by which Cinorf7 achieves
Lal formation.
’EXPERIMENTAL SECTION
General. All sources of materials, molecular biology procedures,
and protein purification procedures are provided in the Supporting
Information.
CinM Dehydration and Cyclization Activities in Vitro.
CinM assay components consisted of 50 mM MOPS, pH 7.5, 10 mM
MgCl2,2 0μM CinA(A 1K) peptide, 2.5 mM ATP, 5 μM enzyme, and
1 mM tris(2-carboxyethyl) phosphine hydrochloride (TCEP) or dithio-
threitol(DTT).MALDI-ToFanalysisafterLysCtreatmentshowedthat
CinM is responsible for four dehydrations in the core region. However,
assays using TCEP and DTT formed side products of +180 or +250 Da
for TCEP and +154 Da for DTT (data not shown). To prevent the
formation of these adducts, enzyme assays were conducted in the
presence of TCEP-immobilized gel (20 μL, Thermo Scientific) in
50 mM MOPS, pH 7.5, 10 mM MgCl2, and 2.5 mM ATP (60 μL final
volume) for 6 h while gently rocking the suspension.
Procedure for LysC Cleavage. Enzymatic assay products were
separated from the immobilized TCEP gel by centrifugation and dried
onacentrivapconcentrator.Theproductswereresuspendedin19μLof
100 mM Tris, pH 8.3, and 2 μL of LysC (0.4 μg/mL in 100 mM Tris,
pH8.3)wasadded.Thecleavagereactionwasincubatedat37Cfor3h
andthendesaltedusingaZipTip(Millipore).Theproductwaselutedin
5 μL of sinapinic acid and analyzed by MALDI-ToF MS.
CinM Cyclization Activity Assay. After incubation of His6-
CinA(A 1K) with His10-CinM, the assay components were separated
from the immobilized TCEP resin by centrifugation, and products were
dried in an eppendorf tube on a centrivap concentrator. The assay
products were resuspended in 100 mM Tris, pH 8.3, 1 mM TCEP, and
5mMiodoacetamideandthenincubatedat25Cfor90mininthedark,
desalted using a C18 ZipTip, and subjected to MALDI-ToF MS.
Hydroxylation Activity Assay with CinX. A solution with the
final concentrations of 100 mM MOPS pH 7.5, 1 mM R-ketoglutaric
acid sodium salt (Sigma), 2 mM of L-(+)-ascorbic acid (Acros), 0.1 mM
ferroussulfate7-hydrate(MallinckrodtChemicals), 20μMpeptide,and
25μMofCinXwaspreparedinafinalvolumeof25μLandincubatedat
room temperature for 1 h. The assay was quenched by the addition of
TFAtoafinalconcentration of0.1%,andtheassaymixturewasdesalted
using a C18 ZipTip and eluted with 5 μL of sinapinic acid. The samples
were then analyzed by MALDI-ToF MS analysis.
Tandem MS Analysis To Determine the Hydroxylation
Site. CinA(1 19) was modified by CinX in vitro and treated with
5 mM TCEP to reduce any disulfides that might have formed. The
peptide was then analyzed by LC-ESI-MSMS using a Synapt ESI
quadrupole ToF Mass Spectrometry System (Waters) equipped with
anAcquity UltraPerformance LiquidChromatography (UPLC)system
(Waters) (Figure S5).13759 dx.doi.org/10.1021/ja205783f |J. Am. Chem. Soc. 2011, 133, 13753–13760
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Coexpression of His6-CinA(A 1K), CinM, and CinX with
and without Cinorf7 in E. coli. To coexpress CinA(A 1K), CinM,
andCinX,E.coliBL21(DE3)cellsweretransformedwithapRSFDuet-1
vector containing cinA(A 1K) and cinM and a pACYCDuet-1 vector
containing cinX. Similarly, for coexpression of His6-CinA(A 1K),
CinM, and CinX together with Cinorf7, E. coli BL21 (DE3) cells were
transformed with a pRSFDuet-1 vector containing cinA(A 1K) and
cinM and a pACYCDuet-1 vector containing cinX and cinorf7. Single
colony transformants were grown in a 37 C shaker for 12 15 h in
50 mL of Luria Bertani (LB) medium supplemented with 25 μg/mL
kanamycin/12.5 μg/mL chloramphenicol. A 20 mL aliquot was cen-
trifuged at 5000g for 10 min, the spent LB medium was discarded, and
the cell pellet was resuspended in fresh LB medium. The resuspended
cells (20 mL) were added to 2 L of LB supplemented with the appro-
priate antibiotics, and the culture was grown aerobically at 37 C until
the A600 was ∼0.6 0.8. IPTG was added to a final concentration of
0.5 mM, and the culture was transferred to 18 C for aerobic growth for
an additional 20 h. Cells were harvested by centrifugation at 5000g for
20minat4C.Thecellpaste(∼3 4g)wasstoredat 80Cuntiluse.
Peptides were puriﬁed from E. coli BL21 (DE3) cultures as described
for other His6-LanA peptides
50 by use of 5 mL HiTrap chelating HP
nickel aﬃnity column (GE Healthcare) followed by HPLC.
Bioactivity Assays with B. subtilis LH45. CinM (5 μM) was
incubated with 50 mM MOPS, pH 7.5, 10 mM MgCl2,2 0μM CinA-
(A 1K) peptide, 2.5 mM ATP, and 150 μL of immobilized TCEP
(600 μL total volume) at 25 C for 6 h. Enzymatic assay products were
separatedfromtheTCEPimmobilizedresinbycentrifugationanddried
via on a centrivap concentrator. The CinM-modified peptide was
resuspended in CinX assay components, and hydroxylation was carried
out for 2 h as described for the CinX assay. The leader peptide was then
cleaved with 15 μL of LysC (0.4 μg/mL in 100 mM Tris, pH 8.3) at
37 C for12 h.The pH ofthe solution was carefully increased to pH 9.5
by addition of 5 M NaOH, and the solution was incubated at room
temperature for 12 h. A solid-phase extraction column (SPE, 1 mL,
Discovery DSC-18) was used to partially purify the peptide from the
assay components. The C18 column was first washed with 2 mL of 80%
acetonitrile(ACN)/waterandequilibratedwith2mLofwater,andthen
thesamplewasapplied.Thecolumnwaswashedwith4mLofwater,and
the samplewas eluted with 1mL 80% ACN/watersolution. Thesample
was dried on a centrivap concentrator, and the peptide was dissolved in
10μLof100mMTrispH7.5,analyzedbyMALDI-MS,andusedforthe
bioassay.
Similarly, 0.5mgofmodiﬁedpeptideobtainedfromthecoexpression
of CinM and CinX (sample A) and from coexpression of CinM, CinX,
and Cinorf7 (sample B) was separately dissolved in 1 mL of 100 mM
Tris-HCl pH 8.3 buﬀer and digested with 50 μL of LysC (0.4 μg/mL in
100 mM Tris, pH 8.3) at 37 C for 12 h. Next, the pH of sample A was
carefullyincreasedtopH9.5byadditionof5MNaOH,andthesolution
wasincubatedatroomtemperaturefor12hfornonenzymaticformation
of Lal. Both samples were then further puriﬁed by SPE as described above.
B. subtilis LH45 was grown at 37 C for 15 h in 5 mL of LB
supplemented with 0.1% D-(+)-glucose (Calbiochem). LB medium
containing 1.5% agar was autoclaved and cooled to 42 C in a water
bath, and 15 mL of this solution was mixed with 375 μLo fB. subtilis
LH45 culture and with a D-(+)-glucose solution to give a 0.1% ﬁnal
glucose concentration. The agar was poured into sterile plates, and
shallow wells were generated after the agar solidiﬁed. The peptide
samples (10μLin 50mMTrisbuﬀer)werespotted, andthe plateswere
incubated for 10 h at 25 C.
’ASSOCIATED CONTENT
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